Roswell Park Cancer Institute

Site:	Roswell Park Cancer Institute
Address:
City:	Buffalo
State:	NY
Zip:	14263
Country:	USA

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
2	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	Active, not recruiting	Withdrawn	LOXO-101	NCT02576431
3	Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor	Terminated	Closed	Imatinib + Bevacizumab	NCT00324987
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047